Physician profile
Thomas Resch
NPI 1609036326
$2,914.92
in general payments reported to CMS, 2019-2025
13 companies · $144 in 2025
The $144 reported for 2025 was less than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $165 · 2020: $81.76 · 2021: $1,218 · 2022: $279 · 2023: $464 · 2024: $562 · 2025: $144.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,171.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,171.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avita Medical Americas, LLC | $1,481.71 | 2020-2023 | Recell |
| Vericel Corporation | $352.01 | 2023-2025 | Nexobrid |
| Polynovo North America LLC | $319.49 | 2022-2024 | Novosorb Btm |
| W. L. Gore & Associates, INC. | $243.61 | 2024 | Gore Tag Thoracic Endoprosthesis |
| Smith+Nephew, INC. | $192.01 | 2019-2023 | Grafix Pl, Oasis, Stravix Pl |
| Boston Scientific Corporation | $146.90 | 2021-2024 | Spyglass Discover |
| Polarityte, INC. | $61.67 | 2019 | |
| Shire North American Group INC | $36.41 | 2019 | |
| Kerecis Limited | $23.29 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
| Melinta Therapeutics, LLC | $16.10 | 2019 | |
| Kci USA, INC. | $15.86 | 2022 | |
| Osiris Therapeutics INC. | $13.27 | 2019 | |
| Medline Industries Lp | $12.59 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Resch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.